Serina's Chemistry Coup: A New Era for its POZ Drug Platform

HUNTSVILLE, AL – December 11, 2025 – In a move that signals a significant strategic acceleration, clinical-stage biotechnology company Serina Therapeutics (NYSE American: SER) has appointed Dr. Joshua Thomas, a veteran of antibody-drug conjugate (ADC) development, as its new Vice President and Head of Chemistry. While leadership changes are common in the fast-paced biotech sector, this particular appointment is far more than a simple personnel update; it is a clear declaration of intent to expand the company’s proprietary POZ Platform™ technology into some of the most complex and lucrative areas of modern medicine.

Dr. Thomas joins Serina from Mersana Therapeutics, where he spent 13 years playing a pivotal role in building its discovery chemistry capabilities and advancing novel ADC technologies. His recruitment is a strategic coup for the smaller, Alabama-based Serina, bringing deep expertise in designing the highly complex linker and “warhead” elements that are critical to the success of targeted cancer therapies. This move positions Serina to leverage its unique polymer technology far beyond its current lead candidate for Parkinson's disease, signaling a calculated pivot towards higher-value, next-generation therapeutics.

A Strategic Capture in the Biotech Talent Wars

The hiring of Dr. Thomas is a powerful indicator of Serina's ambitions and the perceived value of its core technology. Attracting a 13-year veteran from a well-regarded ADC player like Mersana is no small feat and speaks volumes in the competitive biotech talent market. Dr. Thomas's background is particularly noteworthy; he was instrumental in developing a novel STING agonist ADC platform at his former company, a cutting-edge approach in immuno-oncology. His expertise lies in the intricate chemistry of bioconjugation—the science of attaching potent drug payloads to targeting molecules like antibodies—a field that has produced some of oncology's biggest recent breakthroughs.

This isn't a new relationship, but a deepening of an existing one. As Serina's CEO, Steve Ledger, noted, Dr. Thomas has been a consultant and member of the company's Scientific Advisory Board for the past two years. Ledger stated, “Our work with Josh... has already shaped the evolution of our foundational POZ chemistry platform and strategy.” Bringing him fully on board is, as Ledger described it, “a natural step as we push the boundaries of our small molecule opportunity and expand the POZ platform into two new therapeutic modalities.” This transition from advisor to internal leader suggests that the potential Dr. Thomas saw in the POZ platform was compelling enough to warrant a full commitment, validating the technology's promise from an industry insider's perspective.

Unpacking the POZ Platform: A Next-Generation Drug Delivery Engine

At the heart of Serina's strategy is its proprietary POZ Platform™, a technology based on a synthetic polymer called poly(2-oxazoline), or POx. For decades, the biopharmaceutical industry has relied on polyethylene glycol (PEG) to extend the half-life and improve the stability of drugs. However, PEG has known limitations, including potential immune reactions and oxidative degradation. POx is emerging as a next-generation alternative, offering higher stability, greater tunability, and more precise functionalization while maintaining critical features like biocompatibility.

Serina's platform is engineered to give developers greater control over how much drug is attached to the polymer and the precise rate at which it is released in the body. This is crucial for drugs with narrow therapeutic windows, where the line between an effective dose and a toxic one is thin. By creating more stable and predictable drug levels, the POZ platform has the potential to improve efficacy and reduce side effects for a wide range of therapies. This technological edge positions Serina to compete in the enormous drug delivery market, a sector projected to be worth hundreds of billions of dollars within the next decade.

Beyond Parkinson's: Expanding into High-Value Modalities

Serina’s most advanced program is SER-252, a POZ-enabled version of apomorphine for advanced Parkinson's disease. The therapy is designed to provide continuous dopaminergic stimulation, aiming to reduce the debilitating motor complications and “off” episodes that plague patients on standard levodopa therapy. With the global apomorphine market projected to grow steadily, SER-252 represents a significant near-term commercial opportunity, especially with its potential for improved patient convenience through self-administration with a wearable device. The company plans to advance SER-252 into clinical testing in 2025.

However, the appointment of Dr. Thomas clearly signals that Parkinson's is just the beginning. The CEO's mention of expanding into “two new therapeutic modalities” is a crucial clue to the company’s future. Given Dr. Thomas's deep background, the first modality is almost certainly Antibody-Drug Conjugates. The ADC market is explosive, projected to exceed $25 billion by 2030. The POZ platform could offer a superior way to control drug-to-antibody ratios and payload release, addressing key challenges in ADC design.

The second modality is likely RNA-based therapeutics. This is strongly supported by Serina's November 2023 non-exclusive licensing agreement with pharmaceutical giant Pfizer. The deal allows Pfizer to use Serina’s POZ technology in lipid nanoparticle (LNP) formulations, a critical component for delivering RNA-based drugs. Pfizer’s interest serves as a powerful external validation of the platform's potential in one of medicine's most revolutionary fields. Dr. Thomas’s leadership in chemistry will be essential to realizing the platform's potential in both of these complex and highly competitive areas.

Navigating Clinical Hurdles and Financial Realities

Serina's path forward is not without challenges. The company recently submitted a complete response to the FDA regarding a clinical hold on its Investigational New Drug (IND) application for SER-252. The hold was related to a formulation excipient, not the core drug or its mechanism, but it underscores the inherent risks and regulatory hurdles in clinical development. Serina remains confident it can resolve the issue and initiate its Phase 1b trial in the first quarter of 2026.

Financially, the company is positioning itself to execute its ambitious strategy. Following a merger that took it public on the NYSE American in early 2024, Serina has secured financing, including up to $20 million announced in September 2025, specifically to advance SER-252 through registrational trials. This funding, combined with strategic partnerships like the one with Pfizer for technology licensing and another with Enable Injections for a wearable delivery system, provides a foundation for growth.

The hiring of Dr. Joshua Thomas should be viewed as a critical investment in the intellectual capital required to unlock the full value of Serina’s technology. It marks an inflection point, where the company's focus shifts from proving a single concept to building a versatile, multi-program pipeline. With a validated platform, key strategic partnerships, and now a top-tier chemistry leader at the helm, Serina Therapeutics is making a bold play to become a central player in the future of advanced drug delivery.